Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2015 · 10-Q
Revenue$1.75M$1.75M+104.6% vs Q2 2014 Net Income-$9.69M-$9.69MN/M vs Q2 2014 EPS Diluted-$0.12-$0.12N/M vs Q2 2014 Gross Profit$1,749,000+104.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$9,967,179N/M Free Cash Flowderived-$10,195,172N/M Margins · derivedGross margin100.0%−0.1 pt vs Q2 2014
Operating margin-771.6%+756.0 pt vs Q2 2014
Net margin-554.1%+559.4 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 10, 2015 · 41 d after period end